<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12427">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945163</url>
  </required_header>
  <id_info>
    <org_study_id>2016-M-2</org_study_id>
    <nct_id>NCT02945163</nct_id>
  </id_info>
  <brief_title>Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <brief_summary>
    <textblock>
      Tenofovir+lamivudine+efavirenz is still the first line regimen of combination antiretroviral
      therapy in developing countries. Based on our previous data, we aim to evaluate whether
      reduce the dose of tenofovir and efavirenz could decreasing the incidence of the side
      effects while not scarifying their virological efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with HIV RNA&lt;50 Copies/ml</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 200mg + Lamivudine 300mg +Efavirenz 400mg PO Quaque die</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amr 0</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg + Lamivudine 300mg +Efavirenz 600mg PO Quaque die</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Amr 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Amr 0</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Amr 0</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV antibody positive

          -  Chinese nationality

          -  Na√Øve to antiretroviral therapy

          -  Willing to start antiretroviral therapy

          -  Provision of written informed consent

        Exclusion Criteria:

          -  Pregnant, breastfeeding, or lactating

          -  Females try to get pregnant during the research period

          -  Subjects who allergic to any of the research drugs

          -  Subjects that taking other drugs that known to impact the absorption, distribution,
             metabolism and excretion of the research drugs

          -  Any serious or active medical or psychiatric illness which, in the opinion of the
             Investigator, would interfere with treatment, assessment, compliance with the
             protocol, or subject safety. This would include any active clinically significant
             renal, cardiac, pulmonary, vascular, or metabolic (thyroid disorders, adrenal
             disease) illness, or malignancy

          -  Medical or psychiatric condition or occupational responsibilities that may preclude
             compliance with the protocol

          -  Laboratory blood values:

          -  Haemoglobin &lt;9.0 grams/decilitre (g/dL)

          -  Neutrophil count &lt;1500/mm3

          -  Platelet count &lt;75,000/mm3

          -  Aspartate aminotransferase or Alanine transaminase &gt;3 times Upper Limit of Normal
             (ULN)

          -  Total bilirubin &gt;3 times Upper Limit of Normal (ULN)

          -  Subjects with an estimated creatinine clearance of &lt;90 mL/minute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>302 Military Hospital of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lei Shi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yunnan AIDS care center</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xicheng Wang, M.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo No.2 Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>October 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
